Leuprolide (SIF Formulation)
Central Precocious Puberty (CPP)
Phase 3Active (Caspian Study)
Key Facts
Indication
Central Precocious Puberty (CPP)
Phase
Phase 3
Status
Active (Caspian Study)
Company
About Foresee Pharmaceuticals
Foresee Pharmaceuticals is a purpose-driven, clinical-stage biopharma focused on improving patient quality of life through innovative drug delivery and novel therapeutics. Its core strategy is built on two pillars: a proprietary Stabilized Injectable Formulation (SIF) platform for creating long-acting injectables that enhance compliance, and a pipeline of first/best-in-class New Chemical Entities (NCEs) for severe, underserved diseases. Key achievements include advancing multiple programs into late-stage clinical trials, such as FP-045 for Fanconi Anemia and its SIF-based Leuprolide for Central Precocious Puberty, while establishing a global partnership strategy to commercialize its products worldwide.
View full company profile